Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Role of Synaptogyrin-3 in Methamphetamine Self-Administration and Dopamine Dysfunction

Award Number: F31DA066221
ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 11/07/2026
PERIOD OF PERFORMANCE END DATE: 11/06/2027

Group Awards By:

View Award Description

Role of Synaptogyrin-3 in Methamphetamine Self-Administration and Dopamine Dysfunction - PROJECT SUMMARY: Methamphetamine use disorder (MUD) is characterized as a cluster of symptoms associated with chronic use of methamphetamine (METH) despite negative consequences. The number of overdose deaths related to METH use is on the rise. However, there are no FDA approved MUD therapeutics, making generation of novel pharmacotherapies critical. METH functions primarily as a dopamine (DA) releaser and produces its reinforcing effects by elevating DA levels in the mesolimbic DA system, which consists of projections from the ventral tegmental area (VTA) to the nucleus accumbens (NAc). Yet, chronic METH use leads to hypodopaminergia (hypoDA), a state characterized by reduced DA system function that is theorized to promote negative affective states and perpetuate METH use. Therefore, a therapeutic strategy for MUD is to target proteins that facilitate DA transmission, as this could counteract METH-induced DA deficits. One such protein is the synaptic vesicle protein synaptogyrin-3 (Syngr3). The exact mechanisms of Syngr3 activity in DA neurons are unknown, but it is hypothesized to have a role in (1) DA release by regulating exocytosis and vesicle mobility and (2) DA uptake via interactions with the dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT-2). Recent studies in our lab found that viral overexpression of Syngr3 in VTA DA neurons (Syngr3 OE) decreased cocaine (COC) self-administration (SA) and protected against COC-induced deficits in DA transmission. Given the protective role of Syngr3 against COC taking, we wanted to probe whether the findings would translate to METH. The initial hypothesis was that Syngr3 would play a similar protective role; however, preliminary data indicate that Syngr3 OE rats may show increased METH SA behaviors relative to controls. We postulate that the opposing results are because METH produces its effects in part by inducing DAT-mediated DA efflux, a process that Syngr3 could enhance by organizing presynaptic release machinery. Further investigation is needed to gain a deeper insight into Syngr3’s role in modulating MUD-related behaviors and the effects of METH on the DA system. The central hypothesis of this study is that METH taking and METH-induced deficits in DA transmission are facilitated by Syngr3 function in VTA DA neurons. Viral overexpression of Syngr3 in VTA DA neurons will be used to assess the functional consequences of Syngr3 activity. This will ultimately aid in the development of a deeper understanding of Syngr3’s role in regulating DA homeostasis, which can be used as a foundation to guide the development of novel therapeutics for MUD in the future.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $50,114 )
2026	2026	WAKE FOREST UNIVERSITY HEALTH SCIENCES	MEDICAL CENTER BLVD	WINSTON SALEM	NC	27157	FORSYTH	USA	Drug Use and Addiction Research Programs	000	1	5/12/2026	NEW	$50,114
														Subtotal = $50,114

Grand Total All Awards = $50,114

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Role of Synaptogyrin-3 in Methamphetamine Self-Administration and Dopamine Dysfunction

Award Number: F31DA066221

ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 11/07/2026

PERIOD OF PERFORMANCE END DATE: 11/06/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer